Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
Total sales growth of 22.6% at CER1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline®, growing by 27.5% at CER Strong pipeline momentum with three Phase III readouts expected in H2 2026 Confirmation of full-year 2026 guidance2 PARIS, FRANCE, 23 April 2026 – Ipsen (Euronext: IPN; ADR: IPSEY), a […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.